Article
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Translational neurodegeneration - 4 Mar 2024
Lubben Noah, Brynildsen Julia K, Webb Connor M, Li Howard L, Leyns Cheryl E G, Changolkar Lakshmi, Zhang Bin, Meymand Emily S, O'Reilly Mia, Madaj Zach, DeWeerd Daniella, Fell Matthew J, Lee Virginia M Y, Bassett Dani S, Henderson Michael X
Abstract excerpt
BACKGROUND: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson's disease (PD). These mutations elevate the LRRK2 kinase activity, making LRRK2 kinase inhibitors an attractive therapeutic. LRRK2 kinase activity has been consistently linked to specific cell signaling pathways, mostly related to organelle trafficking and homeostasis, but its relationship to PD...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.